I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Friday, March 20, 2015

Second Parkinson’s Vaccine Reports Positive Safety Results

FoxFeed Blog

Posted by Maggie McGuire, March 20, 2015

Second Parkinson’s Vaccine Reports Positive Safety Results

Irish biotechnology company Prothena announced yesterday that its vaccine in development to slow Parkinson’s disease (PD) progression was safe and tolerable in a Phase I study.

This immunotherapy approach introduces an antibody (called PRX002) against the protein alpha-synuclein, which clumps in the brain cells of people with PD. Researchers believe that clearing out the clumps of alpha-synuclein will protect the brain cells from degradation caused by Parkinson’s.

Prothena’s news follows an announcement last July from Austrian biotech AFFiRiS that its MJFF-funded vaccine against alpha-synuclein was also safe and tolerable in a Phase I study. AFFiRiS is now testing a “boost” of that vaccine in the same research volunteers and is planning a Phase II study.

While both immunotherapy drugs, the compound from AFFiRiS prompts the body to generate the antibody against alpha-synuclein while Prothena is introducing the antibody directly. MJFF has not funded Prothena but is consulting on its PRX002 project.

The company tested its drug in 40 healthy volunteers and found that, in addition to safety, treatment was associated with lower alpha-synuclein levels, a promising but early finding.

“We look forward to building upon these data with results from the on-going, multiple ascending dose study in patients with Parkinson's disease expected in the first half of 2016, where we will also be measuring levels of PRX002 in the cerebrospinal fluid and assessing additional biochemical, imaging and clinical biomarker endpoints,” said Gene Kinney, PhD, chief scientific officer and head of research and development at Prothena.

That Phase I study in people with Parkinson’s is recruiting at a number of sites in the United States. Visit Fox Trial Finder to learn more.

Watch a webinar on the role of alpha-synuclein in PD and how researchers are targeting this protein to stop disease progression.

https://www.michaeljfox.org/foundation/news-detail.php?second-parkinson-vaccine-reports-positive-safety-results